OncoMatch/Clinical Trials/NCT05557838
Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma
Is NCT05557838 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Durvalumab and Tremelimumab for hepatocellular carcinoma.
Treatment: Durvalumab · Tremelimumab — This is a prospective, open label, multi-center, interventional study to assess the safety and efficacy of Druvalumab plus Tremelimumab as first-line treatment in Chinese patients with unresectable hepatocellular carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Liver function
child-pugh score class a or b
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05557838 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages